Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07ZAH
|
|||
| Former ID |
DCL001135
|
|||
| Drug Name |
ACH-1625
|
|||
| Synonyms |
SOVAPREVIR; 1001667-23-7; UNII-2ND9V3MN6O; ACH-0141625; 2ND9V3MN6O; Sovaprevir [USAN:INN]; Sovaprevir (USAN); Prodrug of ACH-1095; SCHEMBL1462843; CHEMBL2105750; DTXSID00142994; DB12069; SB16836; D10166; 2-Pyrrolidinecarboxamide, N-((1R,2S)-1-(((cyclopropylsulfonyl)amino)carbonyl)-2- ethenylcyclopropyl)-1-((2S)-3,3-dimethyl-1-oxo-2-(2-oxo-2-(1-piperidinyl)ethyl)butyl)-4-
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 2 | [1] | |
| Company |
Achillion
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C43H53N5O8S
|
|||
| Canonical SMILES |
CC(C)(C)C(CC(=O)N1CCCCC1)C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=CC(=NC6=C5C=CC(=C6)OC)C7=CC=CC=C7
|
|||
| InChI |
1S/C43H53N5O8S/c1-6-28-25-43(28,41(52)46-57(53,54)31-16-17-31)45-39(50)36-22-30(26-48(36)40(51)33(42(2,3)4)23-38(49)47-19-11-8-12-20-47)56-37-24-34(27-13-9-7-10-14-27)44-35-21-29(55-5)15-18-32(35)37/h6-7,9-10,13-15,18,21,24,28,30-31,33,36H,1,8,11-12,16-17,19-20,22-23,25-26H2,2-5H3,(H,45,50)(H,46,52)/t28-,30-,33-,36+,43-/m1/s1
|
|||
| InChIKey |
MHFMTUBUVQZIRE-WINRQGAFSA-N
|
|||
| CAS Number |
CAS 1001667-23-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
3723201, 10039409, 14839657, 16347884, 36059235, 49684228, 80491883, 96025695, 99455178, 103533130, 109693015, 111630651, 123105171, 126578521, 126666050, 126727848, 134223970, 134340525, 134340605, 135692887, 136920427, 137188810, 137273793, 141479428, 143498830, 152234951, 152258142, 152344432, 160645797, 160646981, 162011420, 162197409, 163884617, 164193943, 164765234, 175266405, 175426470, 175427024, 176250091, 184812119, 198992420, 223366200, 223385689, 223669631, 224452297, 226544280, 248618622, 249810645, 249821696, 251916476
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Protease (HIV PR) | Target Info | Inhibitor | [1] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of Achillion (2011). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.